GEN Exclusives

More »

GEN News Highlights

More »
Apr 25, 2012

GEN Poll Points to Belief that Success Rates for Biologics Will Grow

  • By a more than 2-to-1 margin, GEN readers expect the rate of success for biologics in clinical development and approval will increase in coming years. More than half (57.4%) of respondents took that optimistic view, while 27.8% predicted the success rate will decrease, 12.2% believe it will remain relatively flat, and 2.6% were undecided.

    Two studies published in recent weeks along with a pair of studies released over the past two years showcased pharma’s drift toward biologic development and provided evidence of the promise of large molecule drugs. In the most recent report, dated March 23, the U.K. law firm Withers & Rogers found that by 2009, biologics accounted for 60% of patents filed by the top 10 pharma companies and that the gap between filings for large and small molecules grew between 2007 and 2009. The studies suggested that biologics held better prospects than traditional small molecules of advancing from lab to clinic to market, though large molecule success rates in development phases have declined in recent years.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »